---
document_datetime: 2025-12-02 04:51:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere.html
document_name: bevespi-aerosphere.html
version: success
processing_time: 0.1159425
conversion_datetime: 2025-12-24 06:23:22.08286
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bevespi Aerosphere

[RSS](/en/individual-human-medicine.xml/67161)

##### Authorised

This medicine is authorised for use in the European Union

glycopyrronium / formoterol fumarate dihydrate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Bevespi Aerosphere is used for maintenance (regular) treatment. It contains the active substances glycopyrronium bromide and formoterol.

Expand section

Collapse section

## How is Bevespi Aerosphere used?

Bevespi Aerosphere is available as a liquid in a portable inhaler device. The recommended dose is 2 inhalations twice a day.

Patients should be shown how to use the inhaler correctly by a doctor or other healthcare professional.

The medicine can only be obtained with a prescription. For more information about using Bevespi Aerosphere, see the package leaflet or contact your doctor or pharmacist.

## How does Bevespi Aerosphere work?

The two active substances in Bevespi Aerosphere work in different ways to widen the airways and improve breathing in COPD.

Glycopyrronium bromide is a muscarinic receptor antagonist. This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.

Formoterol is a long-acting beta-2 agonist. It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.

## What benefits of Bevespi Aerosphere have been shown in studies?

Three main studies in over 5,000 patients with COPD have shown that Bevespi Aerosphere is effective at improving patients' FEV 1 (the maximum volume of air they can breathe out in one second).

In these studies, patients treated with Bevespi Aerosphere for 24 weeks had FEV 1 increases of around 135 to 150 ml. Patients who received placebo (a dummy treatment), on the other hand, had increases of up to 8 ml or reductions of up to 20 ml.

The studies also showed that Bevespi Aerosphere improved FEV 1 more than the single components in the medicine.

Finally, the studies showed that Bevespi Aerosphere can lead to modest improvements in symptoms such as breathlessness.

## What are the risks associated with Bevespi Aerosphere?

The most common side effects with Bevespi Aerosphere (which may affect up to 1 in 10 people) include headache, nausea (feeling sick), muscle spasms and dizziness.

For the full list of side effects and restrictions of Bevespi Aerosphere, see the package leaflet.

## Why is Bevespi Aerosphere authorised in the EU?

The components in Bevespi Aerosphere are well established treatments of COPD. The combination has been shown to be effective at improving patients' lung function, with both components contributing to this effect. The medicine has also shown some effect on symptoms such as breathlessness although this appears modest.

Side effects are considered mild to moderate in severity and are similar to other COPD medicines.

The European Medicines Agency therefore decided that Bevespi Aerosphere's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Bevespi Aerosphere?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bevespi Aerosphere have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Bevespi Aerosphere are continuously monitored. Side effects reported with Bevespi Aerosphere are carefully evaluated and any necessary action taken to protect patients.

## Other information about Bevespi Aerosphere

Bevespi Aerosphere received a marketing authorisation valid throughout the EU on 18 December 2018.

Bevespi Aerosphere : EPAR - Medicine overview

Reference Number: EMA/752588/2018

English (EN) (74.48 KB - PDF)

**First published:** 05/02/2019

[View](/en/documents/overview/bevespi-aerosphere-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-302)

български (BG) (102.51 KB - PDF)

**First published:**

05/02/2019

[View](/bg/documents/overview/bevespi-aerosphere-epar-medicine-overview_bg.pdf)

español (ES) (74.5 KB - PDF)

**First published:**

05/02/2019

[View](/es/documents/overview/bevespi-aerosphere-epar-medicine-overview_es.pdf)

čeština (CS) (97.77 KB - PDF)

**First published:**

05/02/2019

[View](/cs/documents/overview/bevespi-aerosphere-epar-medicine-overview_cs.pdf)

dansk (DA) (73.01 KB - PDF)

**First published:**

05/02/2019

[View](/da/documents/overview/bevespi-aerosphere-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.51 KB - PDF)

**First published:**

05/02/2019

[View](/de/documents/overview/bevespi-aerosphere-epar-medicine-overview_de.pdf)

eesti keel (ET) (82.96 KB - PDF)

**First published:**

05/02/2019

[View](/et/documents/overview/bevespi-aerosphere-epar-medicine-overview_et.pdf)

ελληνικά (EL) (108.87 KB - PDF)

**First published:**

05/02/2019

[View](/el/documents/overview/bevespi-aerosphere-epar-medicine-overview_el.pdf)

français (FR) (75.09 KB - PDF)

**First published:**

05/02/2019

[View](/fr/documents/overview/bevespi-aerosphere-epar-medicine-overview_fr.pdf)

hrvatski (HR) (93.97 KB - PDF)

**First published:**

05/02/2019

[View](/hr/documents/overview/bevespi-aerosphere-epar-medicine-overview_hr.pdf)

italiano (IT) (73.33 KB - PDF)

**First published:**

05/02/2019

[View](/it/documents/overview/bevespi-aerosphere-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.82 KB - PDF)

**First published:**

05/02/2019

[View](/lv/documents/overview/bevespi-aerosphere-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.2 KB - PDF)

**First published:**

05/02/2019

[View](/lt/documents/overview/bevespi-aerosphere-epar-medicine-overview_lt.pdf)

magyar (HU) (93.32 KB - PDF)

**First published:**

05/02/2019

[View](/hu/documents/overview/bevespi-aerosphere-epar-medicine-overview_hu.pdf)

Malti (MT) (97.98 KB - PDF)

**First published:**

05/02/2019

[View](/mt/documents/overview/bevespi-aerosphere-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.58 KB - PDF)

**First published:**

05/02/2019

[View](/nl/documents/overview/bevespi-aerosphere-epar-medicine-overview_nl.pdf)

polski (PL) (98.74 KB - PDF)

**First published:**

05/02/2019

[View](/pl/documents/overview/bevespi-aerosphere-epar-medicine-overview_pl.pdf)

português (PT) (74.55 KB - PDF)

**First published:**

05/02/2019

[View](/pt/documents/overview/bevespi-aerosphere-epar-medicine-overview_pt.pdf)

română (RO) (102.6 KB - PDF)

**First published:**

05/02/2019

[View](/ro/documents/overview/bevespi-aerosphere-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.78 KB - PDF)

**First published:**

05/02/2019

[View](/sk/documents/overview/bevespi-aerosphere-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.93 KB - PDF)

**First published:**

05/02/2019

[View](/sl/documents/overview/bevespi-aerosphere-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.11 KB - PDF)

**First published:**

05/02/2019

[View](/fi/documents/overview/bevespi-aerosphere-epar-medicine-overview_fi.pdf)

svenska (SV) (73.26 KB - PDF)

**First published:**

05/02/2019

[View](/sv/documents/overview/bevespi-aerosphere-epar-medicine-overview_sv.pdf)

Bevespi Aerosphere :  EPAR - Risk-management-plan summary

English (EN) (317.57 KB - PDF)

**First published:** 05/02/2019

[View](/en/documents/rmp-summary/bevespi-aerosphere-epar-risk-management-plan-summary_en.pdf)

## Product information

Bevespi Aerosphere : EPAR - Product Information

English (EN) (958.75 KB - PDF)

**First published:** 05/02/2019

**Last updated:** 03/12/2024

[View](/en/documents/product-information/bevespi-aerosphere-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-479)

български (BG) (1016.65 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/bg/documents/product-information/bevespi-aerosphere-epar-product-information_bg.pdf)

español (ES) (893.99 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/es/documents/product-information/bevespi-aerosphere-epar-product-information_es.pdf)

čeština (CS) (1.11 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/cs/documents/product-information/bevespi-aerosphere-epar-product-information_cs.pdf)

dansk (DA) (1.07 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/da/documents/product-information/bevespi-aerosphere-epar-product-information_da.pdf)

Deutsch (DE) (1016.9 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/de/documents/product-information/bevespi-aerosphere-epar-product-information_de.pdf)

eesti keel (ET) (1.11 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/et/documents/product-information/bevespi-aerosphere-epar-product-information_et.pdf)

ελληνικά (EL) (973.69 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/el/documents/product-information/bevespi-aerosphere-epar-product-information_el.pdf)

français (FR) (1.18 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/fr/documents/product-information/bevespi-aerosphere-epar-product-information_fr.pdf)

hrvatski (HR) (1.07 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/hr/documents/product-information/bevespi-aerosphere-epar-product-information_hr.pdf)

íslenska (IS) (1013.76 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/is/documents/product-information/bevespi-aerosphere-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/it/documents/product-information/bevespi-aerosphere-epar-product-information_it.pdf)

latviešu valoda (LV) (1.22 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/lv/documents/product-information/bevespi-aerosphere-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.24 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

12/12/2024

[View](/lt/documents/product-information/bevespi-aerosphere-epar-product-information_lt.pdf)

magyar (HU) (952.6 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/hu/documents/product-information/bevespi-aerosphere-epar-product-information_hu.pdf)

Malti (MT) (1.05 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/mt/documents/product-information/bevespi-aerosphere-epar-product-information_mt.pdf)

Nederlands (NL) (1.01 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/nl/documents/product-information/bevespi-aerosphere-epar-product-information_nl.pdf)

norsk (NO) (1.04 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/no/documents/product-information/bevespi-aerosphere-epar-product-information_no.pdf)

polski (PL) (1.08 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/pl/documents/product-information/bevespi-aerosphere-epar-product-information_pl.pdf)

português (PT) (1.15 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/pt/documents/product-information/bevespi-aerosphere-epar-product-information_pt.pdf)

română (RO) (1.13 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/ro/documents/product-information/bevespi-aerosphere-epar-product-information_ro.pdf)

slovenčina (SK) (884.76 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/sk/documents/product-information/bevespi-aerosphere-epar-product-information_sk.pdf)

slovenščina (SL) (1.11 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/sl/documents/product-information/bevespi-aerosphere-epar-product-information_sl.pdf)

Suomi (FI) (1.01 MB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/fi/documents/product-information/bevespi-aerosphere-epar-product-information_fi.pdf)

svenska (SV) (969.8 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

03/12/2024

[View](/sv/documents/product-information/bevespi-aerosphere-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0021 02/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bevespi Aerosphere : EPAR - All Authorised presentations

English (EN) (29.76 KB - PDF)

**First published:** 05/02/2019

**Last updated:** 23/10/2019

[View](/en/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-146)

български (BG) (32.48 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/bg/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.91 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/es/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.78 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/cs/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.89 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/da/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.61 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/de/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (33.51 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/et/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.72 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/el/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_el.pdf)

français (FR) (29.87 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/fr/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (55.5 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/hr/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.62 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/is/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.39 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/it/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.76 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/lv/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.84 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/lt/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.02 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/hu/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (31.7 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/mt/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (28.72 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/nl/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.89 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/no/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.86 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/pl/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.29 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/pt/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.65 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/ro/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.54 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/sk/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.64 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/sl/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.26 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/fi/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (29.17 KB - PDF)

**First published:**

05/02/2019

**Last updated:**

23/10/2019

[View](/sv/documents/all-authorised-presentations/bevespi-aerosphere-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bevespi Aerosphere Active substance

- glycopyrronium
- formoterol fumarate dihydrate

International non-proprietary name (INN) or common name

- glycopyrronium
- formoterol fumarate dihydrate

Therapeutic area (MeSH) Pulmonary Disease, Chronic Obstructive Anatomical therapeutic chemical (ATC) code R03AL07

### Pharmacotherapeutic group

formoterol and glycopyrronium bromide

### Therapeutic indication

Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

## Authorisation details

EMA product number EMEA/H/C/004245 Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 18/10/2018 Marketing authorisation issued 18/12/2018 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bevespi Aerosphere : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (126.98 KB - PDF)

**First published:** 23/10/2019

**Last updated:** 03/12/2024

[View](/en/documents/procedural-steps-after/bevespi-aerosphere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Bevespi Aerosphere : EPAR - Public assessment report

Adopted

Reference Number: EMA/778350/2018

English (EN) (2.63 MB - PDF)

**First published:** 05/02/2019

[View](/en/documents/assessment-report/bevespi-aerosphere-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Bevespi Aerosphere

Adopted

Reference Number: EMA/CHMP/70534/2018

English (EN) (61.56 KB - PDF)

**First published:** 19/10/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-bevespi-aerosphere_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/12/2024

## Share this page

[Back to top](#main-content)